Bacterial protease inhibitors

Medicinal Research Reviews

Volumn 22, Issue 4, 2002, Pages 329-372

  Supuran, Claudiu T ^a   Scozzafava, Andrea ^a   Clare, Brian W ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

AAA protease; Anthrax lethal factor; Antibiotics; Botulinum neurotoxins; Clostridium collagenase; Cysteine protease; degP; Metalloprotease; Serine protease; Sortase; Tetanus neurotoxin

Indexed keywords

AAA PROTEINASE; ANTIBIOTIC AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN INHIBITOR; CLOSTRIPAIN; CLOSTRIPAIN INHIBITOR; COLLAGENASE; COLLAGENASE INHIBITOR; CYSTEINE PROTEINASE; DEG PROTEINASE; METALLOPROTEINASE; PROTEINASE; PROTEINASE INHIBITOR; SERINE PROTEINASE; SIGNAL PEPTIDASE; SIGNAL PEPTIDASE INHIBITOR; SORTASE; TETANUS NEUROTOXIN INHIBITOR; TETANUS TOXIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL CELL WALL; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL INFECTION; CELL PROLIFERATION; CLOSTRIDIUM HISTOLYTICUM; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME SPECIFICITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST; HUMAN; IMMUNE RESPONSE; INHIBITION KINETICS; NONHUMAN; NUTRIENT; PATHOGENESIS; PROTEIN SYNTHESIS; PROTEINASE INHIBITION; REVIEW; RIBOSOME; TISSUE INJURY;

BACTERIA; CYSTEINE PROTEINASE INHIBITORS; SERINE PROTEINASE INHIBITORS;

EID: 0036273016     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10007     Document Type: Review

References (201)

1. Protease inhibitors: Current status and future prospects
2. Structural and biochemical studies of retroviral proteases
3. Bacterial proteinases as targets for the development of second generation antibiotics
4. Bacterial metalloproteases as the toxic factor in infection
5. Role of microbial proteases in pathogenesis
6. Bacterial signals and antagonists: The interaction between bacteria and higher organisms
7. Resisting resistance: New strategies for battling superbugs
8. Evolutionary families of peptidases
9. Mapping the active site of papain with the aid of peptide substrates and inhibitors
10. Introduction: Serine peptidases and their clans
11. Protease inhibitors: Synthesis and QSAR study of novel classes of non-basic thrombin inhibitors incorporating sulfonylguanidine and O-methyl-sulfonyl-isourea moieties at P1
12. Protease inhibitors. Part 2: Weakly basic thrombin inhibitors incorporating sulfonylaminoguanidine moieties as S1 anchoring groups - Synthesis and structure-activity correlations
13. Protease inhibitors. Part 3: Synthesis of non-basic thrombin inhibitors incorporating pyridinium-sulfanilylguanidine moieties at the P1 site
14. Protease inhibitors. Part 4: Synthesis of weakly basic thrombin inhibitors incorporating pyridinium-sulfanilylaminoguanidine moieties
15. Introduction: Tissue kallikrein and its relatives
16. Tryptase
17. Physiological importance of trypsin like protease during morphological differentiation of Streptomyces spp
18. Crystal structure of Sterptomyces erythraeus trypsin at 1.9 A resolution
19. Streptomyces griseus protease B: Secretion correlates with the length of the peptide
20. Streptogrisin B
21. What can the structure of enzyme-inhibitor complexes tell us about the structures of enzyme substrate complexes?
22. Selection of Streptomyces griseus protease B mutants with desired alterations in primary specificity using a library screening strategy
23. Active-site variants of Streptomyces griseus protease B with peptide-ligation activity
24. The 1.8 A structure of the complex between chymostatin and Streptomyces griseus protease A. A model for serine protease catalytic tetrahedral intermediates
25. Synthetic analogues of chymostatin. Inhibition of chymotrypsin and Streptomyces griseus proteinase A
26. Glutamyl endopeptidases
27. Glutamyl endopeptidase I
28. Glutamyl endopeptidase II
29. Synthesis and proteinase inhibitory properties of diphenyl phsophonate analogues of aspartic and glutamic acids
30. The staphylococcal scalded-skin syndrome: Isolation and partial characterization of the exfoliative toxin
31. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome
32. Structural similarities and differences in Staphylococcus aureus exfoliative toxins A and B as revealed by their crystal structures
33. α-lytic protease
34. Relationship between enzyme specificity and the backbone dynamics of free and inhibited α-lytic protease
35. Refined structure of α-lytic protease at 1.7 A resolution. Analysis of hydrogen bonding and solvent structure
36. Purification, staphylolytic activity, and cleavage sites of α-lytic protease from Achromobacter lyticus
37. The HtrA family of serine proteases
38. A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein
39. Degradation by proteases Lon, Clp, and HtrA, of Escherichia coli proteins aggregated in vivo by heat shock; HtrA protease action in vivo and in vitro
40. DegP or protease Do
41. Lysyl endopeptidase
42. Bacteriolytic activity and specificity of Achromobacter beta-lytic protease
43. A comprehensive genetic study of strptococcal immunoglobulin A1 proteases: Evidence for recombination within and between species
44. IgA1-specific serine endopeptidase
45. Immunoglobulin A1 protease, an exoenzyme of pathogenic Neisseriae, is a potent inducer of proinflammatory cytokines
46. Pathogenesis of group A streptococcal infections
47. Group A streptococci in the 1990s
48. Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouose oral mucosa by Streptococcus pyogenes
49. Characterization of the streptococcal C5a peptidase using a C5a-green fluorescent fusion protein substrate
50. Dichelobacter (sheep foot-rot) basic serine proteinase
51. Properties of the extracellular acidic proteases of Dichelobacter nodosus. Stability and specificity of peptide bond cleavage
52. Purification of the extracellular acidic proteases of Dichelobacter nodosus
53. Improved laboratory diagnosis of ovine footrot: An update
54. Molecular pathogenesis of the cell surface proteins and lipids from Treponema denticola
55. Multiple forms of the major phenylalanine specific protease in Treponema denticola
56. Trepolysin
57. Matrix metalloproteinases (MMPs)
58. Tripeptidyl-peptidases A, B, and C
59. Prolyl tripeptidyl peptidase from Porphyromonas gingivalis: A novel enzyme with possible pathological implications for the development of periodontitis
60. Prolyl aminopeptidase gene from Flavobacterium meningosepticum: Cloning, purification of the expressed enzyme, and analysis of its sequence
61. Use of cycloserine-cefoxitin-fructose agar and L-proline-aminopeptidase (PRO Discs) in the rapid identification of Clostridium difficile
62. Crystal structure of prolyl aminopeptidase from Serratia marcescens
63. Structure of proline iminopeptidase from Xanthomonas campestris pv. citri: A prototype for the prolyl oligopeptidase family
64. Streptomyces K15 D-Ala-D-Ala transpeptidase
65. Streptomyces K15 active-site serine DD-transpeptidase: Specificity profile for peptide, thiol ester, and ester carbonyl donors and pathways of the transfer reactions
66. The crystal structure of a penicilloylserine transferase of intermediate penicillin sensitivity. The DD-transpeptidase of streptomyces K15
67. Streptomyces R61 D-Ala-D-Ala carboxypeptidase
68. Beta-secondary and solvent deuterium kinetic isotope effects on catalysis by the Streptomyces R61 DD-peptidase: Comparisons with a structurally similar class C beta-lactamase
69. Functionalized depsipeptides, substrates, and inhibitors of beta-lactamases and DD-peptidases
70. Signal peptidase I
71. Kinetic and mechanistic studies of signal peptidase I from Escherichia coli
72. Penem inhibitors of bacterial signal peptidase
73. Structural features, physiological roles, and biotechnological applications of the membrane proteases of the OmpT bacterial endopeptidase family: A micro-review
74. Identification of active site serine and histidine residues in Escherichia coli outer membrane protease OmpT
75. In vitro folding, purification and characterization of Escherichia coli outer membrane protease ompT
76. Endopeptidase Clp
77. Proteolysis and chaperones: The destruction/reconstruction dilemma
78. Cysteine proteases and their inhibitors
79. Streptopain
80. Streptococcal cysteine proteinase releases kinins: A novel virulence mechanism
81. Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness
82. Clostripain
83. Identification of the active site of legumain links it to caspases, clostripain, and gingipains in a new clan of cysteine endopeptidases
84. Aziridinyl peptides as inhibitors of cysteine proteases: Effect of a free carboxylic acid function on inhibition
85. Investigations on the enzyme specificity of clostripain: A new efficient biocatalyst for the synthesis of peptide isosteres
86. Nonconventional amide bond formation catalysis: Programming enzyme specificity with substrate mimetics
87. Pyroglutamyl peptidase: An overview of the three known enzymatic forms
88. Pyrrolidone carboxyl peptidase (Pcp): An enzyme that removes pyroglutamic acid (pGlu) from pGlu-peptides and pGlu-proteins
89. Prodrugs of peptides. IV. Bioreversible derivatization of the pyroglutamyl group by N-acylation and N-aminoethylation to effect protection against pyroglutamyl aminopeptidase
90. Activation by peptidases and cytotoxicity of 2-(L-a-aminoacyl) prodrugs of methotrexate
91. Role of gingipains R in the pathogenesis of Porphyromonas gingivalis-mediated periodontal disease
92. Periodontal disease: Bacterial virulence factors, host response, and impact on systemic health
93. Gingipain R gingipains K
94. Genetic analyses of proteolysis, hemoglobin binding, and hemagglutination of Porphyromonas gingivalis. Construction of mutants with a combination of rgpA, rgpB, kgp, and hagA
95. A peptide domain on gingipain R, which confers immunity against Porphyromonas gingivalis infection in mice
96. Crystal structure of gingipain R: An Arg-specific bacterial cysteine proteinase with a caspase-like fold
97. Titration and mapping of the active site of cysteine proteinases from Porphyromonas gingivalis (gingipains) using peptidyl chloromethanes
98. New targets for antibiotic development: Biogenesis of surface adherence structures
99. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall
100. Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus, at the LPXTG motif
101. Anchor structure of staphylococcal surface proteins. IV. Inhibitors of the cell wall sorting
102. Anchoring of surface proteins to the cell wall of Staphylococcus aureus
103. Sortase, a universal target for therapeutic agents against gram-positive bacteria?
104. Staphylococcus aureus sortase mutants deffective in the display of surface proteins and in the pathogenesis of animal infection
105. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope
106. Zinc enzymes
107. Bacterial proteases as pathogenic factors, with special emphasis on vibrio proteases
108. Novel pathogenic mechanism of microbial metalloproteinase: Liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor
109. Neurotoxins affecting neuroexocytosis
110. How botulinum and tetanus neurotoxins block neurotransmitter release
111. Thermolysin
112. Purification and characterization of an inducible metalloprotease inhibitor from the hemolymph of greater wax moth larvae, Galleria mellonella
113. Characteristics of the biologically active 35-kDa metalloprotease virulence factor from Listeria monocytogenes
114. The enterococcus faecalis extracellular metalloendopeptidase (EC 3.4.24.30; coccolysin) inactivates human endothelin at bonds involving hydrophobic amino acid residues
115. In vitro proteolytic processing and activation of the recombinant precursor of El Tor cytolysin/hemolysin (pro-HlyA) of Vibrio cholerae by soluble hemagglutinin/protease of V. cholerae, trypsin, and other proteases
116. Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate
117. The role of Pseudomonas aeruginosa elastase as a potent inflammatory factor in a rat air pouch inflammation model
118. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa
119. Pseudolysin
120. Legionella metalloendopeptidase
121. Effects of an isogenic Zn-metalloproteasedeficient mutant of Legionella pneumophila in a guinea-pig pneumonia model
122. Identification of metal ligands in the Clostridium histolyticum ColH collagenase
123. A study of the collagenbinding domain of a 116-kDa Clostridium histolyticum collagenase
124. Vibrio collagenase
125. Clostridium collagenase
126. Purification and separation of individual collagenases of Clostridium histolyticum using red dye ligand chromatography
127. Characterization of the individual collagenases from Clostridium histolyticum
128. Considerations for the use of clostridial collagenase in clinical practice
129. Protease inhibitors: Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties
130. Zinc coordination, function, and structure of zinc enzymes and other proteins
131. D-Phe complexes of zinc and cobalt carboxypeptidase A
132. Carbonic anhydrase and matrix metalloproteinase inhibitors. Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of carbonic anhydrase isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes
133. Protease inhibitors. Part 5. Alkyl/arylsulfonyl- and arylsulfonylureido-/arylureido-glycine hydroxamate inhibitors of Clostridium histolyticum collagenase
134. Protease inhibitors: Synthesis of L-alanine hydroxamate sulfonylated derivatives as inhibitors of Clostridium histolyticum collagenase
135. Protease inhibitors. Part 7. Inhibition of Clostridium histolyticum collagenase with sulfonylated derivatives of L-valine hydroxamate
136. Protease inhibitors. Part 8. Synthesis of potent Clostridium histolyticum collagenase inhibitors incorporating sulfonylated L-alanine hydroxamate moieties
137. Protease inhibitors. Part 9. Synthesis of Clostridium histolyticum collagenase inhibitors incorporating sulfonyl-L-alanine hydroxamate moieties
138. Protease inhibitors. Part 12. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating sulfonylated N-4-nitrobenzyl-βalanine hydroxamate moieties
139. Protease inhibitors. Synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type
140. Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis
141. Effect of collagen cross-linking in collagen corneal shields on ocular drug delivery
142. (TM)) ointment in the debridement of dermal ulcers
143. Considerations for the use of clostridial collagenase in clinical practice
144. The 105-kDa protein component of Bacillus cereu non-hemolytic enterotoxin is a metalloprotease with gelatinolytic and collagenolytic activity
145. Use of liquid chromatography-mass spectrometry coupling for monitoring the serralysin-catalyzed hydrolysis of a peptide library
146. Serralysin
147. Aeruginolysin
148. Mirabilysin
149. Molecular evolution of the pathogenicity island of enterotoxigenic Bacteroides fragilis strains
150. Molecular modeling and analysis of the Bacteroides fragilis toxin
151. Molecular characterization of the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis
152. The enterotoxin of Bacteroides fragilis is a metalloprotease
153. Crystal structure of carboxypeptidase T from Thermoactinomyces vulgaris
154. X-ray structure of aminopeptidase A from Escherichia coli and a model for the nucleoprotein complex in Xer site-specific recombination
155. A bicarbonate ion as a general base in the mechanism of peptide hydrolysis by dizinc leucine aminopeptidase
156. Salmonella enterica serovar typhimurium peptidase B is a leucyl aminopeptidase with specificity for acidic amino acids
157. The extracellular regions of PSMA and the transferrin receptor contain an aminopeptidase domain: Implications for drug design
158. Slow-binding inhibition of the aminopeptidase from Aeromonas proteolytica by peptide thiols: Synthesis and spectroscopic characterization
159. Structure and function of the methionine aminopeptidases
160. Eukaryotic methionyl aminopeptidases: Two classes of cobalt-dependent enzymes
161. Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases
162. Structure of the cobalt-dependent methionine aminopeptidase from Escherichia coli: A new type of proteolytic enzyme
163. Structure and mechanism of proline-specific aminopeptidase from Escherichia coli
164. Glutamate carboxypeptidase
165. Glutamyl hydrolase: Pharmacological role and enzymatic characterization
166. Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy
167. Antibody-enzyme conjugates for cancer therapy
168. Vancomycin, teicoplanin, and ramoplanin: Synthetic and mechanistic studies
169. VanX, a bacterial D-alanyl-D-alanine dipeptidase: Resistance, immunity, or survival function?
170. Dithiol compounds: Potent, time-dependent inhibitors of VanX, a zinc-dependent D,D-dipeptidase required for vancomycin resistance in Enterococcus faecium
171. The structure of VanX reveals a novel amino-dipeptidase involved in mediating transposon-based vancomycin resistance
172. O-Sialoglycoprotein endopeptidase
173. β-lytic metalloendopeptidase
174. Staphylolysin
175. Antibody response to Staphylococcus aureus whole cell, lipase and staphylolysin in patients with S. aureus infections
176. IgA-specific metalloendopeptidase
177. A comprehensive genetic study of streptococcal immunoglobulin A1 proteases: Evidence for recombination within and between species
178. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin
179. Identification of the nerve terminal targets of botulinum neurotoxins serotypes a, D, and E
180. Crystal structure of botulinum neurotoxin type A and implications for toxicity
181. β-amino-thiols inhibit the zinc metallopeptidase activity of tetanus toxin light chain
182. Metallopeptidase inhibitors of tetanus toxin: A combinatorial approach
183. Carbonic anhydrase inhibitors
184. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery
185. Pharmacology of botulinum toxin
186. Botulinum toxin type A for palmar and digital hyperhidrosis
187. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen
188. Anthrax toxin lethal factor
189. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor
190. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages
191. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha
192. The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors
193. Lysostaphin
194. Aminoacid sequence and three-dimensional structure of the Staphylococcus aureus metalloproteinase at 1.72 A resolution
195. Aureolysin
196. AAA proteases: Cellular machines for degrading membrane proteins
197. FtsH - A single chain chaperonin?
198. Second transmembrane segment of FtsH plays a role in its proteolytic activity and homo-oligomerization
199. FtsH recognizes proteins with unfolded structure and hydrolyzes the carboxyl side of hydrophobic residues